Bromodel 2.5 mg 1pcs

Hyperprolactinemia-Associated Dysfunctions: Dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Prolactin-secreting adenomasdn cases where adenectomy is elected, a course of bromocriptine mesilate therapy may be used to reduce the tumor mass prior to surgery.

Acromegaly Parkinson’s Disease: Idiopathic or postencephalitic Parkinson’s disease- As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor)

Antiparkinson drugs, Motility stimulants/Dopamine antagonist

Bromocriptine mesilate is a nonhormonal, nonestrogenic agent that inhibits the secretion of prolactin in humans, with little or no effect on other pituitary hormones, except in patients with acromegaly, where it lowers elevated blood levels of growth hormone. Bromocriptine mesilate is a dopamine receptor agonist, which activates post-synaptic dopamine receptors.The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be dopamine); in the corpus striatum the dopaminergic neurons are involved in the control of motor function. Clinically, it significantly reduces plasma levels of prolactin in patients with physiologically elevated prolactin as well as in patients with hyperprolactinemia.

Hyperprolactinemia (Adult):

• Initial: 1.25 mg to 2.5 mg orally daily.
• Titration: Add 2.5 mg orally, as tolerated, to the treatment dosage every 2 to 7 days.
• Maintenance: 2.5 mg to 15 mg orally daily.

Acromegaly (Adult):

• Initial: 1.25 mg to 2.5 mg orally once daily, with food, at bedtime for 3 days.
• Titration: Add 1.25 mg to 2.5 mg orally, as tolerated, to the treatment dosage every 3 to 7 days.
• Maintenance: 20 mg to 30 mg orally daily
• The maximum dosage should not exceed 100 mg/day.

Parkinson’s Disease (Adult):

• Initial: 1.25 mg twice daily with meals.
• Titration: Add 2.5 mg/day, with meals, to dosage regimen every 14 to 28 days.
• Maximum dosage: 100 mg/day.

Type 2 Diabetes (Adult):

• Initial: 0.8 mg orally daily taken within two hours after waking in the morning with food
• Titration: Increase by 0.8 mg weekly as tolerated
• Maintenance: 1.6 to 4.8 mg orally daily taken within two hours after waking in the morning with food
• The maximum dosage should not exceed 4.8 mg daily.

Hyperprolactinemia (11 to 15 years old):

• Initial: 1.25 mg to 2.5 mg orally daily.
• Maintenance: 2.5 mg to 10 mg orally daily.

 

Bromocriptine may interact with dopamine antagonists, butyrophenones, and certain other agents. Compounds in these categories result in a decreased efficacy of Bromocriptine: phenothi-azines, haloperidol, metodopramide, pimozide. Concomitant use of Bromocriptine with other ergot alkaloids is not recommended.

Uncontrolled hypertension and sensitivity to any ergot alkaloids. In patients being treated for hyperprolactinemia Bromocriptine mesilate should be withdrawn when pregnancy is diagnosed. Post partum period in women with a history of coronary artery disease & other severe cardiovascular conditions

Side effects in decreasing order of frequency are: nausea, headache, dizziness,fatigue, lightheadedness,vomiting .abdominal cramps,nasal congestion,constipation,diarrhea and drowsiness. A slight hypotensive effect may accompany treatment.The occurrence of adverse reactions may be lessened by temporarily reducing dosage to 0.5 mg. Abnormalities in laboratory tests may include elevations in blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.

Pregnancy category B. Bromocriptine should not be used during lactation in postpartum women.

Pediatric use: No data are available for bromocriptine use in pediatric patients under the age of 8 years

Store in cool and dry place. Protect from light and moisture.